CN113429418B - 一种柠檬酚c-3位乙酰化化合物的制备方法及应用 - Google Patents
一种柠檬酚c-3位乙酰化化合物的制备方法及应用 Download PDFInfo
- Publication number
- CN113429418B CN113429418B CN202110808604.9A CN202110808604A CN113429418B CN 113429418 B CN113429418 B CN 113429418B CN 202110808604 A CN202110808604 A CN 202110808604A CN 113429418 B CN113429418 B CN 113429418B
- Authority
- CN
- China
- Prior art keywords
- limonol
- compound
- ethyl acetate
- acetylated
- liver cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZFIURKZEANVFML-RVWQQJOKSA-N limonol Chemical compound C=1([C@@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)[C@H](O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 ZFIURKZEANVFML-RVWQQJOKSA-N 0.000 title claims abstract description 52
- ZFIURKZEANVFML-UHFFFAOYSA-N limonol Natural products CC1(C)OC2CC(=O)OCC22C1CC(O)C(C13OC1C(=O)O1)(C)C2CCC3(C)C1C=1C=COC=1 ZFIURKZEANVFML-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 150000001875 compounds Chemical class 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 201000007270 liver cancer Diseases 0.000 claims abstract description 15
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract description 39
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 abstract description 23
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003208 petroleum Substances 0.000 abstract description 6
- 238000000926 separation method Methods 0.000 abstract description 5
- 239000003054 catalyst Substances 0.000 abstract description 4
- 239000003480 eluent Substances 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 238000000746 purification Methods 0.000 abstract description 4
- 238000010898 silica gel chromatography Methods 0.000 abstract description 4
- 230000021736 acetylation Effects 0.000 abstract description 3
- 238000006640 acetylation reaction Methods 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000010992 reflux Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 244000046101 Sophora japonica Species 0.000 description 4
- 235000010586 Sophora japonica Nutrition 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000015817 Infant Nutrition disease Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- -1 benzopyran ring flavone Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000522190 Desmodium Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000019631 acid taste sensations Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003034 coal gas Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000003350 kerosene Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003079 shale oil Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000271 synthetic detergent Substances 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种柠檬酚C‑3位乙酰化化合物的制备方法,制备步骤如下:(1)按比例取柠檬酚4‑6mg、乙酸乙酯4‑6mL、吡啶0.5‑1.5 mL、乙酸酐0.5‑1.5 mL;(2)将柠檬酚溶于乙酸乙酯中,以吡啶为催化剂,在室温下与的乙酸酐反应12‑13h;(3)反应完成后,以石油醚为洗脱剂,硅胶柱层析分离纯化得到柠檬酚C‑3位乙酰化化合物。本方法制备得到的柠檬酚C‑3位乙酰化化合物选择性好,对人肝癌HepG2细胞具有较好的抑制作用,是良好的治疗肝癌药物候选化合物。
Description
技术领域
本发明涉及化合物制备的技术领域,具体是一种柠檬酚C-3位乙酰化化合物的制备方法及应用。
背景技术
小槐花Desmodium caudatum (Thunb.) DC.为豆科山蚂蝗属植物,为广西壮、瑶民族常用药材,被收载于《广西中药材标准》、《广西壮族自治区壮药质量标准》、《中国瑶药学》。小槐花壮药名为棵文沾,瑶药名为握麻红,主要分布于广西、安徽、浙江、江西等省。中医认为其味甘、苦、凉,具有清热解毒,祛风透疹,消积止痛功效,用于感冒发热,疹出不透,小儿疳积,脘腹疼痛,泄泻。壮医认为其味甜、苦,平,调龙路,通气道谷道,清热毒,止血,用于心头痛(胃痛),白冻(泄泻),月经不调,喯疳(疳积),贫痧(感冒),北嘻(乳痈),狠尹(疖肿)。瑶药认为其味苦,性凉,清热解毒,消积,散瘀利水,健脾开胃,用于治咳嗽、吐血、水肿、胃脘痛、小儿疳积、跌打损伤、痈疮溃疡、烧烫伤溃烂。
本申请人前期对壮瑶药小槐花进行了深入的研究,并从中提取分离出了一种A环并吡喃环黄酮结构的化合物柠檬酚;随后的活性研究发现,该化合物可通过破坏人肝癌HepG2细胞的F-actin骨架,阻止纺锤体形成,从而抑制癌细胞的增殖,并呈剂量依赖性,提示柠檬酚具有潜在的抗肿瘤作用。经深入研究发现A环并吡喃环黄酮具有良好的生物活性,鉴于柠檬酚的A环并吡喃环黄酮结构,在A环C-3位位点进行结构修饰,能提高其抗肿瘤活性、增加选择性,获得良好的抗肿瘤药物候选化合物。
发明内容
本发明的目的是提供一种柠檬酚C-3位乙酰化化合物的制备方法,该方法制备得到的柠檬酚C-3位乙酰化化合物具有抗肿瘤活性高、毒性低、选择性好,是良好的抗肿瘤药物候选化合物。
本发明是采用以下技术方案实现的:
一种柠檬酚C-3位乙酰化化合物的制备方法,其制备步骤如下:
(1)按比例取柠檬酚4-6mg、乙酸乙酯4-6mL、吡啶0.5-1.5 mL、乙酸酐0.5-1.5 mL。
(2)将柠檬酚溶于乙酸乙酯中,以吡啶为催化剂,在室温下与的乙酸酐反应12-13h。
(3)反应完成后,以石油醚为洗脱剂,硅胶柱层析分离纯化得到柠檬酚C-3位乙酰化化合物。柠檬酚的结构式为:
柠檬酚C-3位乙酰化化合物的结构式:
乙酰基在C-3位置与柠檬酚的羟基结合。
进一步优选的:所述的柠檬酚的纯度为95%以上。
进一步优选的:所述的柠檬酚从小槐花中提取。
小槐花中提取柠檬酚的步骤为:
a、原料预处理:取小槐花茎或/和叶部位晾干、粉碎得到样品。
b、回流浓缩:将样品放入回流装置中,加入乙醇回流,得到回流提取液,再将回流提取液蒸发,浓缩,得到液状浸膏。
c、制样:将液状浸膏加入柱层析硅胶和乙醇拌样,蒸干,直至得到分散状样品。
d、柱层析分离:将柱层析硅胶放入层析柱内,加入乙酸乙酯至可流动状固液混合物,打开层析柱活塞,用乙酸乙酯冲洗至柱层析硅胶紧密,将分散状样品加入到层析柱内,用乙酸乙酯洗脱层析柱,等量收集各个流份,然后确认柠檬酚是否出来完全,富集含有柠檬酚的部分流份,蒸发,得到柠檬酚。
进一步优选的:上述技术方案中,步骤b中乙醇回流提取为,用样品体积5-20倍量的体积浓度为30-90%的乙醇加热回流提取,回流时间为l-3h。
进一步优选的:上述技术方案中,乙醇加热回流提取的温度是85-100℃。
进一步优选的:上述技术方案中,步骤c中乙醇的体积浓度为30-90%;加入柱层析硅胶的量为浓缩后液状浸膏质量的1.0-1.2倍。
进一步优选的:上述技术方案中,步骤(4)中柱层析硅胶的量为分散状样品质量的10-20倍。
进一步优选的:上述技术方案中,步骤d中收集流份的量的体积为层析柱内乙酸乙酯保留体积的1/10-1/5。
本方法制备得到的柠檬酚C-3位乙酰化化合物在制备治疗肝癌药物中的应用,是良好的治疗肝癌药物候选化合物。
乙酸乙酯是无色透明液体,英文名:ethyl acetate,乙酸乙酯低毒性,有甜味,浓度较高时有刺激性气味,易挥发,对空气敏感,能吸水分,使其缓慢水解而呈酸性反应。
吡啶,有机化合物,是含有一个氮杂原子的六元杂环化合物。可以看做苯分子中的一个(CH)被N取代的化合物,故又称氮苯,无色或微黄色液体,有恶臭。吡啶及其同系物存在于骨焦油、煤焦油、煤气、页岩油、石油中。吡啶在工业上可用作变性剂、助染剂,以及合成一系列产品(包括药品、消毒剂、染料等)的原料。
乙酸酐的英文名:Acetic anhydride,无色透明液体,有强烈的乙酸气味,味酸,有吸湿性,溶于氯仿和乙醚,缓慢地溶于水形成乙酸,与乙醇作用形成乙酸乙酯。相对密度1.080g/cm3,熔点-73℃,沸点139℃,折光率1.3904,闪点49℃,燃点 400℃。低毒,半数致死量(大鼠,经口)1780mg/Kg。易燃,有腐蚀性,勿接触皮肤或眼睛,以防引起损伤,有催泪性。
石油醚是无色透明液体,有煤油气味。主要为戊烷和己烷的混合物。不溶于水,溶于无水乙醇、苯、氯仿、油类等多数有机溶剂。主要用作溶剂及作为油脂的抽提。 用作有机溶剂及色谱分析溶剂;用作有机高效溶剂、医药萃取剂、精细化工合成助剂等;也可用于有机合成和化工原料。 用于有机合成和化工原料,如制取合成橡胶、塑料、锦纶单体、合成洗涤剂、农药等,亦是很好的有机溶剂。主要用作溶剂,也用作发泡塑胶的发泡剂,药物、香精的萃取剂。
本柠檬酚C-3位乙酰化化合物的制备方法,是鉴于柠檬酚的A环并吡喃环黄酮结构,在A环C-3位位点进行结构修饰,将柠檬酚溶于乙酸乙酯中,以吡啶为催化剂,在室温下与乙酸酐反应,反应完成后以石油醚为洗脱剂,硅胶柱层析分离纯化得到的柠檬酚C-3位乙酰化化合物,得到的柠檬酚C-3位乙酰化化合物选择性好,对人肝癌HepG2细胞具有较好的抑制作用,柠檬酚C-3位乙酰化化合物对人肝癌HepG2细胞的抑制效果优于柠檬酚对人肝癌HepG2细胞的抑制效果,柠檬酚C-3位乙酰化化合物是良好的治疗肝癌药物候选化合物。
附图说明
图1为柠檬酚C-3位乙酰化化合物的结构表征示意图;
图2为柠檬酚C-3位乙酰化化合物的核磁共振异核多碳相关谱;
图3为柠檬酚C-3位乙酰化化合物的抗肿瘤活性折线图;
采用NMR对柠檬酚C-3位乙酰化化合物进行表征,使用NMR的HMBC确定乙酰基的位置,乙酰基在C-3位置与柠檬酚的羟基结合。其中,核磁共振采用500MHz核磁共振仪(美国Bruker)。
具体实施方式
下面结合实施例,对发明中的技术方案进行清楚、完整地描述,所描述的实施例仅仅是本发明的一部分,而不是全部的实施例。
实施例1
采用以下步骤可制备得到柠檬酚C-3位乙酰化化合物:5 mg柠檬酚溶于5mL的乙酸乙酯中,以1mL的吡啶为催化剂,在室温下与1mL的乙酸酐反应12h,反应完成后,以石油醚为洗脱剂,硅胶柱层析分离纯化得到柠檬酚C-3位乙酰化化合物。
所述的柠檬酚从小槐花中提取,其纯度为95%以上。
制备得到的柠檬酚C-3位乙酰化化合物抗肿瘤活性试验如下:
将待测细胞(HepG2、MDA-MB-231、HT-29、U87)其中,MDA-MB-231细胞购自美国ATCC细胞,传至96孔板培养板中,每孔接种细胞约10000个。置于细胞培养箱中培养24h后,吸取上清培养液,加入不同药物浓度的培养液(200 μg/mL、100 μg/mL、50 μg/mL、25 μg/mL、12.5 μg/mL),每孔100 μL,同一浓度设置6个复孔,继续置于细胞培养箱中培养24 h,检测时将CCK-8试剂与无血清的培养液按1:10比例配制工作液,每孔加入100 μL工作液,放入二氧化碳培养箱中37 ℃恒温孵育1 h,放入全波长酶标仪中,在450 nm波长下检测吸光度,SPSS16.0计算药物半数抑制浓度(IC50)。
柠檬酚C-3位乙酰化化合物对细胞的抑制率统计见下表。
柠檬酚对人肝癌HepG2细胞增殖抑制率统计见下表。
不同质量浓度柠檬酚C-3位乙酰化化合物作用于人肝癌HepG2细胞24 h后,对人肝癌HepG2细胞有一定的呈剂量依赖性的抑制作用,且柠檬酚C-3位乙酰化化合物对人肝癌HepG2细胞的抑制效果优于其它细胞,也优于柠檬酚对人肝癌HepG2细胞的抑制效果。
上述说明并非是对本发明的限制,本发明也并不限于上述实例,本技术领域的普通技术人员,在本发明的实质范围内,作出的变化、改型、添加或替换,都应属于本发明的保护范围。
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110808604.9A CN113429418B (zh) | 2021-07-16 | 2021-07-16 | 一种柠檬酚c-3位乙酰化化合物的制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110808604.9A CN113429418B (zh) | 2021-07-16 | 2021-07-16 | 一种柠檬酚c-3位乙酰化化合物的制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113429418A CN113429418A (zh) | 2021-09-24 |
CN113429418B true CN113429418B (zh) | 2022-11-29 |
Family
ID=77760753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110808604.9A Active CN113429418B (zh) | 2021-07-16 | 2021-07-16 | 一种柠檬酚c-3位乙酰化化合物的制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113429418B (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104592246A (zh) * | 2013-10-30 | 2015-05-06 | 周亚伟 | 一种黄酮类化合物及其制备方法和应用 |
CN109776559B (zh) * | 2019-03-22 | 2021-06-04 | 苏州广奥医药开发有限公司 | 一种全合成制备脱水淫羊藿素的方法 |
CN110964028A (zh) * | 2019-12-16 | 2020-04-07 | 广西壮族自治区中医药研究院 | 小槐花中柠檬酚的提取方法及其用途 |
-
2021
- 2021-07-16 CN CN202110808604.9A patent/CN113429418B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN113429418A (zh) | 2021-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111704544B (zh) | 一种半日花烷型二萜类化合物及其分离方法和应用 | |
CN105503786B (zh) | 裂木脂素类化合物—荨麻裂环木脂素苷e及其制备方法 | |
CN110818669A (zh) | 沉香四氢2-(2-苯乙基)色酮类化合物及其分离方法和应用 | |
RU2758255C1 (ru) | Новое соединение, способ его получения и применение | |
CN111018877B (zh) | 一种土木香中倍半萜类衍生物、其制备方法及应用 | |
CN113429418B (zh) | 一种柠檬酚c-3位乙酰化化合物的制备方法及应用 | |
CN111205302B (zh) | 一种大果木姜子果实提取物、提取方法及制备方法和应用 | |
CN107880084B (zh) | 从凌霄属植物花中提取制备高纯度毛蕊花糖苷的方法 | |
CN107722096B (zh) | 一种具有抗肿瘤作用的甾体类天然药物及其制备方法和用途 | |
CN105949266A (zh) | 睡茄交酯类化合物及提取方法及应用 | |
CN113248483A (zh) | 天胡荽黄酮苷类单体异牡荆素的制备方法及应用 | |
CN114436802A (zh) | 一种杜松烷倍半萜化合物及其制备方法和应用 | |
CN109091602B (zh) | 韭菜子有效成分、提取方法及其在制备保护肝损伤药物方面的应用 | |
CN107383129A (zh) | 一种香豆素苷类化合物及其制备方法和应用 | |
CN102188564A (zh) | 具有抗癌活性的独角莲超临界提取物及其制备方法 | |
CN113004299A (zh) | 山竹皮中具有降低餐后血糖的呫吨酮类化合物及其提取方法和应用 | |
CN105418727A (zh) | 一种新的乌苏烷型二萜类化合物及其制备方法和医药用途 | |
CN105418717A (zh) | 一种用于治疗白血病的甾体类化合物及其制备方法 | |
CN112920146B (zh) | 倍半萜类化合物及其制备方法和在制备抗炎药物中的应用 | |
CN110452278A (zh) | 臭七次生代谢物及其制备方法与其在制药中的应用 | |
CN113248382B (zh) | 一种抗氧化化合物及其制备方法和应用 | |
CN115611844B (zh) | 一种从关苍术中分离得到的化合物的制备方法和应用 | |
CN115521322B (zh) | 一种异戊烯基黄酮化合物及制备方法和应用 | |
CN116333029B (zh) | 一类油茶籽皂苷化合物及其应用 | |
CN111407787B (zh) | 一种异丙醇胺有机酸离子液体提取艾草黄酮的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210924 Assignee: GUANGXI JIAJIN PHARMACEUTICAL Co.,Ltd. Assignor: GUANGXI INSTITUTE OF CHINESE MEDICINE & PHARMACEUTICAL SCIENCE Contract record no.: X2023980046070 Denomination of invention: Preparation Method and Application of a C-3 Acetylation Compound of Lemonol Granted publication date: 20221129 License type: Common License Record date: 20231108 |
|
EE01 | Entry into force of recordation of patent licensing contract |